Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Flumazenil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 known ✓ | P18507 | 16/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 16/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 16/20 | 1.00 |
| ▸ | GABRA1 known ✓ | P14867 | 15/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 14/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 14/20 | 1.00 |
| ▸ | GABRA6 known ✓ | Q16445 | 10/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 8/20 | 1.00 |
| ▸ | GABRA4 known ✓ | P48169 | 4/20 | 1.00 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 1.00 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 1.00 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 1.00 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 1.00 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 1.00 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 1.00 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flumazenil SCHEMBL29444064 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL16187025 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL11885881 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL5781309 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL79030 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL29746432 | 1.00 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL12484498 | 0.99 | GABRG2 (0.98) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL29085132 | 0.97 | GABRG2 (0.94) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| Flumazenil SCHEMBL29025825 | 0.94 | GABRG2 (0.88) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL16479000 | 0.92 | GABRG2 (0.85) | GABRG2GABRB3GABRA5GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250229109-A1 | MONITORING TISSUE PERMEABILITY DURING ULTRASOUND PROCEDURES | INSIGHTEC LTD (IL) | 2025-07-17 | — | — | US | disclosed |
| EP-4496618-A2 | MONITORING TISSUE PERMEABILITY DURING ULTRASOUND PROCEDURES | Insightec Ltd. (IL) | 2025-01-29 | — | — | EP | disclosed |
| CN-119233843-A | Monitoring tissue permeability during ultrasound procedures | 医视特有限公司 | 2024-12-31 | — | — | CN | disclosed |
| WO-2023180811-A2 | MONITORING TISSUE PERMEABILITY DURING ULTRASOUND PROCEDURES | INSIGHTEC LTD. (IL) | 2023-09-28 | — | — | WO | disclosed |
| US-20230181462-A1 | Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-06-15 | — | — | US | disclosed |
| US-11622738-B2 | PET/MRI insert system | SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD. (CN) | 2023-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181462-A1 | Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof | CDC37, ILK, PTMS | GABRG2 2162/4885GABRB3 3134/4885GABRA5 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.